Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints
In this randomized trial of more than 9300 subjects with T2DM and high cardiovascular risk, liraglutide was seen to decrease the incidence of the composite cardiovascular primary endpoint (occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (13.0 and 14.9% in the liraglutide and placebo group, respectively
The GLP-1 effect is also influencing consumer behavior and product choices in weight management
Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB
